Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
NCT00509769Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2007
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in HER2-positive metastatic breast cancer, sponsored by Genentech. Started Jul 2007; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00509769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509769.